MG
ANAB icon

Marex Group’s AnaptysBio ANAB Stock Holding History

Marex Group’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
+4,962
New +$301K ﹤0.01% 822

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Marex Group's ANAB Position: Q2 2026 in Review

Marex Group opened a new position in AnaptysBio (ANAB) in Q2 2026: 4,962 shares worth $335K. The stake represents ﹤0.01% of the portfolio and ranks #822 among its holdings.

213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Marex Group held 4,962 shares of AnaptysBio worth $335K as of Q2 2026.
  • AnaptysBio was a new Marex Group position in Q2 2026.
  • AnaptysBio made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #822 holding.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.